Nevertheless, a phase I/Ib study with AZD9150 (ISIS481464), an antisense oligonucleotide targeting STAT3, has been performed in 58 patients with advanced/metastatic HCC (ClinicalTrials.gov Identifier: NCT01839604). The gene discussed is STAT3; the disease is hepatocellular carcinoma.